Quantum-Si incorporated (QSI)

Quantum-Si incorporated (QSI) Healthcare & Pipeline Overview

Quantum-Si incorporated is a biotechnology company specializing in next-generation protein sequencing technology. Their single-molecule detection platform, utilizing semiconductor technology, targets the proteomics market. With a focus on sample preparation and sequencing, Quantum-Si aims to enable advancements in life sciences research and diagnostics, competing in the broader biotechnology landscape.

What Is the Investment Thesis for QSI?

Quantum-Si incorporated presents a notable research candidate within the biotechnology sector, driven by its innovative single-molecule detection platform for protein sequencing. The company's technology addresses a critical need in proteomics, offering the potential to revolutionize drug discovery and diagnostics. Key value drivers include the successful commercialization of its platform, expansion into new markets, and strategic partnerships with pharmaceutical and research institutions. The company's high beta of 3.09 indicates significant volatility, reflecting the high-growth potential and inherent risks associated with early-stage biotechnology companies. Upcoming catalysts include the launch of new products and the publication of research validating the platform's capabilities. However, the company's negative profit margin of -5605.9% and gross margin of -200.5% highlight the challenges of achieving profitability in the near term. Investors should carefully consider the risks associated with the company's financial performance and the competitive landscape before making investment decisions.

Based on FMP financials and quantitative analysis

QSI Key Highlights

• Market capitalization of $188.41M reflects investor valuation of Quantum-Si's technology and future growth potential.
• Negative profit margin of -5605.9% indicates significant investment in research and development and commercialization efforts.
• Negative gross margin of -200.5% suggests challenges in achieving cost-effective production and pricing strategies.
• Beta of 3.09 indicates high volatility compared to the market, reflecting the speculative nature of the stock.
• Absence of dividend yield reflects the company's focus on reinvesting earnings to fuel growth and innovation.

Who Are QSI's Competitors?

QSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are QSI's Key Strengths?

• Innovative single-molecule detection platform.
• Strong intellectual property portfolio.
• Experienced management team.

What Are QSI's Weaknesses?

• Negative profit and gross margins.
• Limited commercial track record.
• High dependence on research and development.

What Could Drive QSI Stock Higher?

• Launch of new products and applications for its platform.
• Publication of research validating the platform's capabilities.
• Strategic partnerships with pharmaceutical and diagnostic companies.
• Expansion into new geographic markets.

What Are the Key Risks for QSI?

• Negative return on equity (-47.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve profitability in the near term.
• Intense competition from established players in the biotechnology industry.
• Regulatory hurdles and delays in product approvals.
• Dependence on research and development funding.
• Challenges in scaling up production and commercialization.

What Are the Growth Opportunities for QSI?

• Expansion into the pharmaceutical sector: Quantum-Si can capitalize on the growing demand for proteomics solutions in drug discovery and development. By partnering with pharmaceutical companies, Quantum-Si can integrate its platform into their research workflows, accelerating the identification of drug targets and improving the efficiency of clinical trials. The pharmaceutical proteomics market is estimated to reach $25 billion by 2030, presenting a significant growth opportunity for Quantum-Si.
• Penetration of the diagnostics market: Quantum-Si's technology can be applied to develop novel diagnostic assays for a wide range of diseases. By partnering with diagnostic companies, Quantum-Si can commercialize its platform for clinical applications, enabling earlier and more accurate disease detection. The diagnostics market is estimated to reach $100 billion by 2028, offering a substantial growth opportunity for Quantum-Si.
• Geographic expansion into international markets: Quantum-Si can expand its global reach by targeting key international markets, such as Europe and Asia. By establishing partnerships with local distributors and research institutions, Quantum-Si can increase its market share and diversify its revenue streams. The international proteomics market is growing rapidly, driven by increasing investments in healthcare and research.
• Development of new applications for its platform: Quantum-Si can expand its product offerings by developing new applications for its single-molecule detection platform. This includes expanding into areas such as biomarker discovery, personalized medicine, and agricultural biotechnology. By diversifying its product portfolio, Quantum-Si can reduce its reliance on specific markets and increase its overall growth potential.
• Strategic partnerships and collaborations: Quantum-Si can accelerate its growth by forming strategic partnerships and collaborations with other companies and research institutions. This includes partnerships with pharmaceutical companies, diagnostic companies, and academic research centers. By leveraging the expertise and resources of its partners, Quantum-Si can accelerate the development and commercialization of its technology.

What Opportunities Does QSI Have?

• Growing demand for proteomics solutions.
• Expansion into new markets and applications.
• Strategic partnerships and collaborations.

What Threats Does QSI Face?

• Intense competition in the biotechnology industry.
• Rapid technological advancements.
• Stringent regulatory requirements.

What Are QSI's Competitive Advantages?

• Proprietary single-molecule detection platform.
• Patent protection for its technology.
• Expertise in semiconductor technology and proteomics.

What Does QSI Do?

Quantum-Si incorporated, founded in 2013 and headquartered in Guilford, Connecticut, is a life sciences company dedicated to revolutionizing proteomics through its innovative single-molecule detection platform. The company's core technology leverages semiconductor technology to enable next-generation protein sequencing, offering a unique approach to sample preparation and analysis. Quantum-Si's platform is designed to provide researchers and clinicians with unprecedented insights into the proteome, facilitating advancements in drug discovery, diagnostics, and personalized medicine. The company's focus is on developing and commercializing its proprietary technology, positioning itself as a key player in the evolving field of proteomics. By offering a platform that can analyze individual protein molecules, Quantum-Si aims to overcome the limitations of traditional protein analysis methods, providing more detailed and accurate data. This technology has applications across various sectors, including pharmaceuticals, biotechnology, and academic research. Quantum-Si's strategic focus on innovation and its commitment to advancing proteomics positions it for growth in the life sciences industry. The company operates primarily in the United States, with plans to expand its global reach as it commercializes its platform and expands its product offerings. Quantum-Si's mission is to empower researchers and clinicians with the tools they need to unlock the full potential of proteomics, driving advancements in healthcare and improving patient outcomes.

What Products and Services Does QSI Offer?

• Develops a single-molecule detection platform.
• Offers solutions for sample preparation in proteomics.
• Provides next-generation protein sequencing technology.
• Leverages semiconductor technology for protein analysis.
• Enables advancements in drug discovery and diagnostics.
• Offers tools for researchers and clinicians to analyze proteins at the single-molecule level.

How Does QSI Make Money?

• Develops and sells single-molecule detection platforms.
• Generates revenue through sales of consumables and reagents.
• Offers service contracts for platform maintenance and support.

What Industry Does QSI Operate In?

Quantum-Si operates within the dynamic and rapidly evolving biotechnology industry, specifically targeting the proteomics market. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The global proteomics market is projected to reach billions of dollars in the coming years, driven by increasing demand for personalized medicine, drug discovery, and diagnostics. Quantum-Si's single-molecule detection platform positions it to compete with established players in the protein sequencing market, offering a unique approach that could disrupt traditional methods. The company's success will depend on its ability to effectively commercialize its technology, secure strategic partnerships, and navigate the complex regulatory landscape.

Who Are QSI's Key Customers?

• Pharmaceutical companies
• Biotechnology companies
• Academic research institutions

Quantum-Si incorporated Financial Trajectory

Quantum-Si incorporated (QSI) reported $258K in revenue for Q1 2026, a decline of 42.8% compared to the prior quarter. The company recorded a net loss of $21.7M, with diluted EPS of $-0.10. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, QSI averaged $-0.13 in diluted EPS.

Company Profile

Quantum-Si incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Guilford, US. The company is led by CEO Jeffrey Alan Hawkins. QSI has traded publicly since 2020.

How Quantum-Si incorporated Is Valued

Quantum-Si incorporated carries a market capitalization of $188.41M, placing it in the micro-cap category. Relative to its peer group, QSI's quantitative score of 23/100 is below the peer average of 81/100.

ROE -47%Key Financial Metrics

Return on equity for Quantum-Si incorporated stands at -47.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -58.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -58.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Quantum-Si incorporated's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.26 places it in the safe zone, indicating low near-term bankruptcy risk.

5/8 beatsEarnings Track Record

Quantum-Si incorporated has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 11.4% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Quantum-Si incorporated revenue of about $1.0M for fiscal 2026, with EPS near $-0.43.

Net buyingInsider Activity

Over the past six months, Quantum-Si incorporated insiders filed 10 SEC Form 4 transactions — 8 sales and 2 purchases. On net that is roughly 426K shares acquired (about $358K) — insiders putting money in tends to read as conviction.

QSI Financials

QSI Latest News

QSI Analyst Consensus

QSI MoonshotScore

Quantum-Si incorporated Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources